- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.11. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 11 | SEC Filings | ||
| 29.10. | LakeShore Biopharma erfüllt wieder Nasdaq-Anforderungen | 2 | Investing.com Deutsch | ||
| 25.10. | LakeShore Biopharma to test simplified rabies vaccine regimen | 2 | Investing.com | ||
| 25.10. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 25.10. | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine | 288 | PR Newswire | GAITHERSBURG, Md., Oct. 25, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical... ► Artikel lesen | |
| LAKESHORE BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 10.10. | XFRA H6Z0: WIEDERAUFNAHME/RESUMPTION | 150 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 08.10. | LakeShore Biopharma provides HY guidance | 1 | Seeking Alpha | ||
| 08.10. | LakeShore Biopharma projects steady growth for FY2025 | 1 | Investing.com | ||
| 08.10. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 08.10. | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance | 119 | PR Newswire | GAITHERSBURG, Md., Oct. 8, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering... ► Artikel lesen | |
| 04.10. | XFRA H6Z0: AUSSETZUNG/SUSPENSION | 218 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILLAKESHORE BIOP.... ► Artikel lesen | |
| 04.10. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 04.10.2024 | 285 | Xetra Newsboard | The following instruments on XETRA do have their first trading 04.10.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 04.10.2024
Aktien
1 US59564R8079 Biodexa Pharmaceuticals... ► Artikel lesen | |
| 03.10. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 03.10.2024 | 392 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 03.10.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 03.10.2024ISIN NameUS59564R7089 BIODEXA... ► Artikel lesen | |
| 03.10. | XFRA ISIN CHANGE | 560 | Xetra Newsboard | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen CA3874371147 Granite REIT LP 03.10.2024 CA3874372053 Granite REIT LP 04.10.2024 Tausch 1:1US86323X1063 Streamline... ► Artikel lesen | |
| 01.10. | XFRA H6Z: AUSSETZUNG/SUSPENSION | 217 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILLAKESHORE BIOP.DL-... ► Artikel lesen | |
| 27.09. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 27.09. | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation | 134 | PR Newswire | GAITHERSBURG, Md., Sept. 27, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering... ► Artikel lesen | |
| 04.09. | LakeShore Biopharma appoints Wang as CEO | 1 | Seeking Alpha | ||
| 04.09. | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.08. | YS Biopharma reports FY results | 1 | Seeking Alpha |
Seite:
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,550 | 0,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,357 | +0,28 % | Defence Therapeutics will proprietäre Accum-Technologie an Entwickler von Antikörper-Wirkstoff-Konjugaten (ADC) lizenzieren | Vancouver, BC, Kanada, 29. November 2024 / IRW-Press / Defence Therapeutics Inc. ("Defence" oder das "Unternehmen") (CSE: DTC, OTCQB: DTCFF, FWB: DTC), ein kanadisches biopharmazeutisches
Unternehmen... ► Artikel lesen | |
| GINKGO BIOWORKS | 11,100 | 0,00 % | Ginkgo Bioworks CFO Mark Dmytruk veräußert Aktien im Wert von 7.146 US-Dollar | ||
| RECURSION PHARMACEUTICALS | 8,010 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma | First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesizedREC-1245... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,710 | 0,00 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,840 | -0,59 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort | Early safety and tolerability results from six randomized patients support continued enrollment of pelareorep combined with modified FOLFIRINOX, with or without... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 19,090 | 0,00 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,941 | 0,00 % | Assertio Holdings, Inc.: Assertio Reports Third Quarter 2024 Financial Results | Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 6,970 | 0,00 % | General Atomics Electromagnetic Systems: General Atomics Completes SiGA Cladded Nuclear Fuel Rod Irradiation Testing | SAN DIEGO, CA / ACCESSWIRE / December 4, 2024 / General Atomics Electromagnetic Systems (GA-EMS) announced today that unfueled nuclear fuel rods using the company's SiGA® fuel cladding successfully... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,800 | 0,00 % | Looking Into ADMA Biologics' Recent Short Interest | ||
| VIR BIOTECHNOLOGY | 8,320 | 0,00 % | Vir Biotechnology EVP Vanina de Verneuil verkauft Aktien im Wert von 624 US-Dollar | ||
| VERVE THERAPEUTICS | 6,465 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 18,200 | 0,00 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,550 | 0,00 % | Here's Why Summit Therapeutics Stock Price Rose 6% on Friday | ||
| ARVINAS | 25,925 | 0,00 % | Arvinas Inc.: Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update | - On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 - - Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be presented... ► Artikel lesen |
LAKESHORE BIOPHARMA CO LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,220 (-8,59 %) liegt der Kurs bei 2,340 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LAKESHORE BIOPHARMA CO LTD finden Sie auf Wallstreet Online.
